U.S. health regulators are expected to make public on Friday a staff review about the promising Covid-19 pill from Merck & Co. and Ridgeback Biotherapeutics LP.
The report from Food and Drug Administration staff is expected to include an analysis of clinical-trial data for the drug, molnupiravir, which the companies say reduces the risk of hospitalization and dying in people at high risk of severe Covid-19 infections.
